DARVON-N
LOE Approachingpropoxyphene napsylate
NDAORALTABLET
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
DARVON-N (propoxyphene napsylate) is clinical pharmacology pharmacology propoxyphene is a centrally acting opiate analgesic. First approved in 1971.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N (propoxyphene napsylate) is an oral opioid analgesic approved in 1971 for pain management, acting as a centrally acting opiate with additional local anesthetic and cardiac ion channel effects. The drug works through mu-opioid receptor agonism and inhibition of sodium channels (local anesthetic effect) and hERG potassium channels. It is indicated for mild to moderate pain relief in patients requiring opioid analgesia.
LOE Approaching
With lifecycle approaching loss-of-exclusivity and minimal linked job opportunities (0 positions), this brand faces significant commercial contraction and reduced team expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacology Propoxyphene is a centrally acting opiate analgesic. In vitro studies demonstrated propoxyphene and the metabolite norpropoxyphene inhibit sodium channels (local anesthetic effect) with norpropoxyphene being approximately 2-fold more potent than propoxyphene and…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.